durvalumab,pembrolizumab,pemetrexed,cisplatin,gemcitabine
astrazeneca,merck
['imfinzi', 'keytruda', 'nsclc', 'sclc', 'astrazeneca']
asco: keytruda scores phase iii nsclc win, outperforms astrazeneca s imfinzi 
EIN Presswire is Everyone's Internet News Presswire™. We make issuing and distributing press releases easy and affordable.